| Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer (NCT07251582) | Hunan Province Tumor Hospital | 2026-08-12 |
| The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or Metastatic NSCLC With HER2 Over Expression (NCT07662473) | Hunan Province Tumor Hospital | 2026-07-29 |
| Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC (NCT06706219) | Hunan Province Tumor Hospital | 2026-05-10 |
| Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression (NCT07001995) | Hunan Province Tumor Hospital | 2026-05-01 |
| Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer (NCT07477808) | Hunan Province Tumor Hospital | 2026-04-01 |
| The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer (NCT06477055) | Hunan Province Tumor Hospital | 2025-12-02 |
| Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer (NCT06828757) | Hunan Province Tumor Hospital | 2025-05-01 |
| AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC (NCT06196814) | Hunan Province Tumor Hospital | 2024-10-01 |
| Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases (NCT06537297) | Hunan Province Tumor Hospital | 2024-09-30 |
| Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction (NCT06604351) | Hunan Province Tumor Hospital | 2024-09-15 |
| Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (NCT06348927) | Hunan Province Tumor Hospital | 2024-07-01 |
| Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (NCT06355609) | Hunan Province Tumor Hospital | 2024-07-01 |
| Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK (NCT05266846) | Hunan Province Tumor Hospital | 2024-05-29 |
| Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases (NCT06440954) | Hunan Province Tumor Hospital | 2024-05-01 |
| The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC (NCT06109558) | Hunan Province Tumor Hospital | 2023-12-31 |
| A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer (NCT05991193) | Hunan Province Tumor Hospital | 2023-12-29 |
| Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer (NCT05991180) | Hunan Province Tumor Hospital | 2023-12-25 |
| Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (NCT05296278) | Hunan Province Tumor Hospital | 2023-12-25 |
| A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC (NCT05991206) | Hunan Province Tumor Hospital | 2023-12-25 |
| The Efficacy and Safety of IBI363 in Solid Tumors (NCT06081907) | Hunan Province Tumor Hospital | 2023-12-25 |
| JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (NCT04951947) | Hunan Province Tumor Hospital | 2023-06-01 |
| Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB (NCT05295212) | Hunan Province Tumor Hospital | 2023-02-01 |
| Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy (NCT05584267) | Hunan Province Tumor Hospital | 2022-12-25 |
| Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC (NCT05549037) | Hunan Province Tumor Hospital | 2022-09-23 |
| Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement (NCT06073938) | Hunan Province Tumor Hospital | 2022-09-20 |
| To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC (NCT05805267) | Hunan Province Tumor Hospital | 2022-09-20 |
| Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients (NCT05450081) | Hunan Province Tumor Hospital | 2022-06-30 |
| High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases (NCT05379803) | Hunan Province Tumor Hospital | 2022-05-01 |
| Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer (NCT05284539) | Hunan Province Tumor Hospital | 2022-04-01 |
| ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma (NCT05014464) | Hunan Province Tumor Hospital | 2021-11-13 |
| Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer (NCT05059951) | Hunan Province Tumor Hospital | 2021-10-03 |
| Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors (NCT05055908) | Hunan Province Tumor Hospital | 2021-10-01 |
| Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC (NCT04997382) | Hunan Province Tumor Hospital | 2021-08-17 |
| The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. (NCT04777084) | Hunan Province Tumor Hospital | 2021-08-01 |
| A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma (NCT05984017) | Hunan Province Tumor Hospital | 2021-07-01 |
| SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma (NCT04937972) | Hunan Province Tumor Hospital | 2021-07-01 |
| Efficacy of Osimertinib in Patients With Lung Cancer (NCT06174857) | Hunan Province Tumor Hospital | 2021-01-01 |
| Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC (NCT06001671) | Hunan Province Tumor Hospital | 2020-10-27 |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (NCT04322890) | Hunan Province Tumor Hospital | 2020-04-16 |
| Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC (NCT04322578) | Hunan Province Tumor Hospital | 2020-03-24 |
| Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC (NCT04324151) | Hunan Province Tumor Hospital | 2020-03-24 |
| Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC (NCT04324164) | Hunan Province Tumor Hospital | 2020-03-24 |
| Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial (NCT04322591) | Hunan Province Tumor Hospital | 2020-03-24 |
| Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC (NCT04324125) | Hunan Province Tumor Hospital | 2020-03-24 |
| Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer (NCT04322617) | Hunan Province Tumor Hospital | 2020-03-24 |
| A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer (NCT06183762) | Hunan Province Tumor Hospital | 2020-01-01 |
| Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC (NCT05261438) | Hunan Province Tumor Hospital | 2019-09-01 |
| Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer (NCT05055947) | Hunan Province Tumor Hospital | 2019-04-01 |
| Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer (NCT05055999) | Hunan Province Tumor Hospital | 2019-04-01 |
| Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study (NCT03798743) | Hunan Province Tumor Hospital | 2019-01-01 |
| Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients (NCT05129462) | Hunan Province Tumor Hospital | 2018-08-05 |
| Survival Outcomes of Lung Cancer (NCT03647098) | Hunan Province Tumor Hospital | 2018-08-01 |
| Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer (NCT03646994) | Hunan Province Tumor Hospital | 2018-08-01 |
| Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer (NCT03647592) | Hunan Province Tumor Hospital | 2018-06-01 |
| The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis (NCT05326906) | Hunan Province Tumor Hospital | 2018-05-01 |
| Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment (NCT05205226) | Hunan Province Tumor Hospital | 2018-01-02 |
| Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer (NCT03647111) | Hunan Province Tumor Hospital | 2018-01-01 |